Anatomical main group
N – NERVENSYSTEM
57Decisions
73Patient groups
Added benefit by patient group
- Considerable9
- Minor4
- Non-quantifiable5
- Not proven54
- Lesser benefit1
Subgroups
- N01 ANÄSTHETIKA 1 decision
- N02 ANALGETIKA 11 decisions
- N03 ANTIEPILEPTIKA 13 decisions
- N04 ANTIPARKINSONMITTEL 2 decisions
- N05 PSYCHOLEPTIKA 6 decisions
- N06 PSYCHOANALEPTIKA 9 decisions
- N07 ANDERE MITTEL FÜR DAS NERVENSYSTEM 15 decisions
Decisions, newest first
- 2026-06-18ByfavoRemimazolamNot proven
- 2026-06-18ByfavoRemimazolamNot proven
- 2026-05-07AttrogyDiflunisalNot proven
- 2026-04-16KisunlaDonanemabNot proven: 2 of 2 patient groups
- 2026-02-19LeqembiLecanemabNot proven: 2 of 2 patient groups
- 2026-01-22AmvuttraVutrisiranNot proven
- 2025-12-18SkyclarysOmaveloxolonNot proven
- 2025-11-20VyduraRimegepantNot proven
- 2025-11-20VyduraRimegepantNot proven: 2 of 2 patient groups
- 2025-10-16WainzuaEplontersenNot proven
- 2025-08-21AquiptaAtogepantNot proven: 2 of 2 patient groups
- 2024-12-19QalsodyTofersenNon-quantifiable
- 2024-08-15QuviviqDaridorexantNot proven
- 2024-05-16EpidyolexCannabidiolNot proven
- 2024-05-16EpidyolexCannabidiolNot proven
- 2024-05-16EpidyolexCannabidiolNot proven
- 2024-05-16OnpattroPatisiranLesser benefit
- 2023-10-05RayvowLasmiditanNot proven
- 2023-09-21WakixPitolisantNon-quantifiable
- 2023-09-21SpravatoEsketaminConsiderable
- 2023-08-03FinteplaFenfluraminConsiderable
- 2023-04-06AmvuttraVutrisiranMinor
- 2023-02-16VyeptiEptinezumabNot proven: 2 of 2 patient groups
- 2022-09-01Briviact (in Italy: Nubriveo)BrivaracetamNot proven
- 2022-07-21SedacondaIsofluranNot proven
- 2022-04-21OzawadePitolisantNot proven
- 2022-03-18SunosiSolriamfetolNot proven
- 2021-11-19OntozryCenobamatNot proven
- 2021-10-21AimovigErenumabConsiderable
- 2021-08-19SpravatoEsketaminMinor
- 2021-07-15FinteplaFenfluraminConsiderable
- 2021-06-03FycompaPerampanelNot proven
- 2021-06-03FycompaPerampanelNot proven
- 2021-05-20VyndaqelTafamidisConsiderable
- 2021-05-20VyndaqelTafamidisNot proven
- 2020-11-05SunosiSolriamfetolNot proven: 2 of 2 patient groups
- 2019-11-07AjovyFremanezumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-10-17Elvanse AdultLisdexamfetamindimesilatNot proven: 2 of 2 patient groups
- 2019-09-19EmgalityGalcanezumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-05-02AimovigErenumabConsiderable
- 2019-03-22OnpattroPatisiranConsiderable
- 2019-03-22TegsediInotersenNon-quantifiable
- 2019-01-17Briviact (in Italy: Nubriveo)BrivaracetamNot proven
- 2018-11-01SativexExtrakt aus Cannabis sativaMinor
- 2018-10-04ReagilaCariprazinMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2018-05-17FycompaPerampanelNot proven
- 2017-03-16OngentysOpicaponNot proven
- 2017-01-19WakixPitolisantNon-quantifiable
- 2017-01-19HetliozTasimelteonNon-quantifiable
- 2016-08-04Briviact (in Italy: Nubriveo)BrivaracetamNot proven
- 2015-11-05XadagoSafinamidNot proven
- 2015-10-15BrintellixVortioxetinNot proven: 3 of 3 patient groups
- 2015-04-16LatudaLurasidonNot proven: 2 of 2 patient groups
- 2015-02-19SelincroNalmefenNot proven
- 2014-11-06FycompaPerampanelNot proven
- 2013-11-14ElvanseLisdexamfetamindimesilatNot proven
- 2012-08-02FampyraFampridinNot proven
Data status: 2026-10-29